MDS Completes Sale of Late-Stage Pharma Services Group | GenomeWeb

NEW YORK (GenomeWeb News) – Toronto-based MDS said today that it has completed the divestiture of its Phase II-IV Pharma Services operations to INC Research, a contract research organization based in Raleigh, NC.

Under the terms of the agreement, INC Research has acquired MDS Pharma Services' Phase II-IV operations, which includes approximately 800 employees who conduct clinical trials in more than 25 countries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.